Physician profile
Gary S Gabelman
NPI 1750393716
$2,325.13
in general payments reported to CMS, 2019-2025
14 companies · $786 in 2025
The $786 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $139 · 2021: $600 · 2022: $94.01 · 2023: $397 · 2024: $308 · 2025: $786.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,492.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,491.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $600.00 | 2021 | |
| Abbott Laboratories | $417.31 | 2023-2025 | Jot Dx, Aveir, Cardiomems |
| Astrazeneca Pharmaceuticals LP | $294.19 | 2019-2025 | Farxiga, Brilinta |
| Novartis Pharmaceuticals Corporation | $213.03 | 2023-2025 | |
| Boston Scientific Corporation | $180.25 | 2025 | Watchman Flx, Watchman Access System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $162.87 | 2023-2025 | Jardiance |
| Genzyme Corporation | $125.00 | 2019 | |
| Pfizer INC. | $118.78 | 2022-2025 | |
| Irhythm Technologies, INC. | $62.47 | 2023 | Zio Xt Patch |
| Celgene Corporation | $48.76 | 2024 | Camzyos |
| E.R. Squibb & Sons, L.L.C. | $35.60 | 2022 | |
| Scpharmaceuticals INC. | $23.14 | 2025 | |
| Abbvie INC. | $22.96 | 2025 | |
| Bridgebio Pharma, INC. | $20.77 | 2025 | Attruby |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Gabelman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.